FORT WAYNE, Ind. -- (BUSINESS WIRE) -- Matrix-Bio, Inc., a leader in metabolomics-based cancer diagnostics, has named Deborah J. Neff to its Board of Directors. Palo Alto, California-based Neff is a veteran of the life sciences industry, with experience in building market-leading global businesses and product commercialization. Over the last 25 years, Neff has served as worldwide president of BD Biosciences, Inc., a business unit of Becton Dickinson; and president and CEO of Predicant Biosciences, Inc., and Pathwork Diagnostics, Inc. Her work in cancer diagnostics includes establishing a CLIA/CA/NY-certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines.
Matrix-Bio is using advanced metabolite profiling to identify the unique metabolite signature of cancer cells in blood serum samples with greater accuracy than established tests. The company’s VeraMarker™ BCR test detects the recurrence of breast cancer with twice the accuracy and 11 months earlier than the current CA 27-29 test. In April 2013, Matrix-Bio licensed biomarkers to Quest Diagnostics, which is developing a clinical lab test for breast cancer recurrence. Matrix-Bio is now focused on developing a suite of metabolite-based colon cancer tests for recurrence, diagnostic screening and treatment monitoring.
Commenting on her appointment, Neff said, “Cancer is a complex disease that affects each person’s metabolism differently. I am impressed by Matrix-Bio’s work in metabolite profiling as a diagnostic and monitoring tool. The company’s leadership, application of their technology, and thoughtful approach to commercialization bodes well for success.”
Neff also serves on the board of Bio-Rad, Inc., and is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation, Inc., which were acquired by Abbott and Pall Corporation respectively. Neff is a member of the Dean’s Leadership Council at the University of California, Davis (UC Davis) College of Biological Sciences. She earned a B.S. in Physiology from UC Davis, and completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.
Said Matrix-Bio CEO Eric Beier, “Deb is an outstanding addition to our board. Her extensive experience in the clinical diagnostic market makes her a tremendous asset and advisor to us as we move forward with our new suite of colon cancer tests.”
For information, visit www.matrix-bio.com.